Acurx Advances Ibezapolstat into Recurrent CDI Trials, Aims to Shift Treatment Paradigm

Event summary

  • Acurx to launch a new clinical trial for ibezapolstat in patients with multiply-recurrent CDI, aiming to shift treatment from two agents to one.
  • Phase 2 results showed 96% clinical cure rate and 100% sustained cure in ibezapolstat-treated patients.
  • Trial enrollment expected to begin in Q4 2026, with up to 20 patients with at least 3 CDI episodes in the past 12 months.
  • Acurx plans to request FDA approval for treatment and prevention of rCDI under the Limited Population Pathway for Antibacterial and Antifungal Drugs.
  • Company has received FDA QIDP and Fast-Track Designation, and EMA SME designation.

The big picture

Acurx's move to address recurrent CDI with ibezapolstat comes as the infection remains a significant public health burden, with approximately 500,000 cases annually in the U.S. and a recurrence rate of up to 40% following standard treatments. The company's strategy to combine treatment and prevention in a single agent could disrupt the current two-agent approach, potentially reducing healthcare costs and improving patient outcomes. The broader industry is watching as regulatory pathways for antibiotics evolve, with FDA considering a shift to a one-trial requirement for registration.

What we're watching

Regulatory Pathway
Whether FDA's potential shift to a one-trial requirement for registration will streamline Acurx's approval process.
Clinical Efficacy
How ibezapolstat's ability to maintain a healthy gut microbiome will impact recurrence rates in Phase 3 trials.
Market Potential
The pace at which Acurx can secure funding and commence international Phase 3 trials for the broader CDI population.